Clinical Trials Browser

Solid Malignancies × tremelimumab × 90 days × Clear all

NCT02537418 2026-03-27

Durvalumab With or Without Tremelimumab in Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens

Phase 1 Active not recruiting

Solid Malignancies